A b s t r a c t
Traditional Chinese medicines are readily available in health food stores in the United States. The use of Chinese medicines as a part of complementary and alternative medicines is no longer limited to the Asian population in the United States. They also are used widely by the general population. For example, according to a survey, Asian ginseng is the most popular complementary and alternative medicine used in the United States. 1 Dan Shen, a traditional Chinese medicine prepared from the root of a Chinese medicinal plant, Salvia miltiorrhiza, has been used in China for many years in the treatment of various cardiovascular diseases, including angina pectoris. Dan Shen is capable of dilating coronary arteries and slowing the heart rate 2 and also is used in the treatment of cerebrovascular diseases and insomnia. 3 Li et al 4 demonstrated dose-dependent hypotensive effects of Dan Shen with positive inotropic and negative chronotropic effects. Dan Shen protects lowdensity lipoprotein from copper dichloride-induced lipid peroxidation. 5 More than 20 diterpene quinones (tanshinones) have been isolated from Dan Shen root extract. These compounds have a common structural feature, a phenanthrene quinone ring structure. 6 Wahed and Dasgupta 7 and Dasgupta et al 8 reported digoxin-like immunoreactivity of Dan Shen in vitro and also in vivo in a mouse model.
Lu-Shen-Wan, "6 miracle pills" in Chinese, contains 6 medicines: Niu Huang (Calculus bovis), Zhen Zhu (Margarita), Xiong Huang (Realgar), Bing Pian (Borneol), Chan Su (Bufo melanostictus), and She Xiang (Secretio moschus). It is used as a remedy for sore throat, dysphagia, abdominal pain, and agitation. Lu-Shen-Wan also shows cardiotonic effects owing to the presence of bufalin and related bufanodienolides. These active components also are present in the Chinese medicine Chan Su. Panesar, 9 using the fluorescence polarization immunoassay (FPIA) for digoxin, reported an apparent digoxin concentration of 0.88 ng/mL (1.13 nmol/L) in healthy volunteers who ingested Lu-ShenWan. Because Dan Shen and Lu-Shen-Wan have cardioactive properties, overdoses from these unregulated Chinese medicines can be troublesome.
The Fab fragment of polyclonal antidigoxin antibody preparation (Digibind, Burroughs Wellcome, Research Triangle Park, NC) is useful in treating severe poisoning with digoxin and digitoxin. [10] [11] [12] Antidigoxin antibody had been used speculatively and was associated with rapid resolution of toxic effects in a patient who ingested an herbal internal cleansing product (possibly containing Digitalis lantana) and had the clinical features of cardiac glycoside toxic effects. 13 Digibind binds the free fraction of oleandrin in vitro because oleandrin has structural similarity with digoxin. 14 Eddleston et al 15 concluded that antidigoxin Fab fragments are safe and effective for treating patients poisoned with yellow oleander.
Antidigoxin Fab fragment antibodies also have been used to treat poisoning with toad venom. 16 The most toxic components of toad venom are the cardioactive steroids bufalin, cinobufotalin, and cinobufagin. These sterols have structural similarity with digoxin. Because the active components of Dan Shen and Lu-Shen-Wan have structural similarity with digoxin, we studied the possibility of neutralizing the digoxin-like immunoreactive components of these traditional Chinese medicines by using Digibind. To our knowledge, the possibility of binding the active components of Dan Shen or Lu-Shen-Wan using Digibind has not been studied before.
Materials and Methods
Lu-Shen-Wan and Dan Shen were purchased from an herbal store in the Chinatown area of Houston, TX. Only 1 brand of Lu-Shen-Wan was available; however, 3 brands of Dan Shen were available commercially, and we purchased all 3 brands. The FPIA for digoxin was purchased from Abbott Laboratories (Abbott Park, IL), and the assay was run using a TDx/FLx analyzer (Abbott Laboratories). Centrifree Micropartition System filters for preparing the protein-free ultrafiltrate of serum were purchased from Amicon (Danvers, MA).
The standard solution of Dan Shen (25 mg/mL) was prepared in ethyl acetate, while the standard solution of LuShen-Wan (1 mg/mL) was prepared in distilled water. In the first experiment, 1-mL aliquots of drug-free serum were supplemented with 25 µL of ethyl acetate extract of each of the 3 brands of Dan Shen. To avoid the matrix effect due to ethyl acetate, we added ethyl acetate extract to a test tube, and the ethyl acetate was evaporated under nitrogen. Then the dry residue was reconstituted with 1 mL of drug-free serum. The apparent digoxin concentration was measured by using the FPIA for digoxin. In subsequent experiments, we used the Dan Shen preparation that showed the highest apparent digoxin concentration in the first experiment.
In the next set of experiments, we supplemented 3 sets of drug-free serum pools with various concentrations of Dan Shen to prepare Dan Shen pools 1, 2, and 3. Then aliquots of each supplemented pool were supplemented further with Digibind to achieve final Digibind concentrations of 5, 10, and 20 µg/mL. After incubation for 1 hour in a water bath at 37°C, we measured the free digoxin concentrations (in the protein-free ultrafiltrate) by using the FPIA for digoxin. The protein-free ultrafiltrate of serum was prepared by centrifuging the specimen for 20 minutes at 2,500g using the Centrifree Micropartition System. Each measurement was performed in triplicate, and the values were expressed as the mean and 1 SD. We also supplemented aliquots of 3 other drug-free serum pools with various amounts of Lu-ShenWan to prepare Lu-Shen-Wan pools 1, 2, and 3. Again, aliquots of supplemented pools were supplemented further with various amounts of Digibind (final concentrations: 5, 10, and 20 µg/mL), and after 1 hour of incubation at 37°C, the free apparent digoxin concentrations were measured.
The FPIA for digoxin requires sample pretreatment. For this purpose, 200 µL of serum was treated with 200 µL of sulfosalicylic acid in methanol to precipitate serum proteins. After centrifugation, the clear supernatant was used for further analysis. To keep the matrix as unaltered as possible, we also added a precipitating agent to the protein-free ultrafiltrate before performing the digoxin assay. As expected, no protein precipitation was observed. The FPIA for digoxin is linear up to a digoxin concentration of 5.0 ng/mL (6.41 nmol/L), and the detection limit of the assay is 0.20 ng/mL (0.26 nmol/L). Therefore, any value less than 0.20 ng/mL (<0.26 nmol/L) was considered as "none detected." All measurements were performed in triplicate, and the values were expressed as the mean and 1 SD.
To demonstrate that protein-free ultrafiltrate is a valid matrix for measuring apparent digoxin concentrations due to the presence of Dan Shen or Lu-Shen-Wan, we prepared protein-free ultrafiltrates from 6 drug-free serum pools. Drug-free serum pool 1 was supplemented with Dan Shen extract. We also supplemented the ultrafiltrate prepared from drug-free serum pool 1 with the same amount of Dan Shen extract and then compared apparent digoxin concentrations observed in the serum specimen with the corresponding value observed in the protein-free ultrafiltrate specimen. To validate the reproducibility of the results, we also supplemented drug-free serum pools 2 and 3 with Dan Shen extract. The corresponding ultrafiltrates also were supplemented with Dan Shen extract. Drug-free serum pools 3 to 6 and the corresponding ultrafiltrates were supplemented with Lu-Shen-Wan extract.
We measured apparent free digoxin to demonstrate that Digibind can neutralize the free digoxin-like immunoreactive components of Dan Shen and Lu-Shen-Wan. The total digoxin measurement is affected by Digibind, but the free digoxin measurement is not because Digibind, owing to its high molecular weight, is absent in the protein-free ultrafiltrate. To demonstrate that Digibind also affects the apparent total digoxin measurement due to Lu-Shen-Wan, we prepared a Lu-Shen-Wan serum pool showing an apparent digoxin concentration of 7.20 ng/mL (9.22 nmol/L) by supplementing a drug-free serum pool with Lu-Shen-Wan. Another aliquot of the drug-free serum pool was supplemented with digoxin to achieve an apparent digoxin concentration of 7.36 ng/mL (9.43 nmol/L) for comparison. Then to aliquots of each supplemented pool, we added various concentrations of Digibind (5, 10, and 20 µg/mL), and the total digoxin concentration was measured by using the FPIA.
Statistical analyses were performed using the 2-tailed Student t test. We considered a value statistically significant only at a confidence of 95% or higher (P < .05).
Results
Dan Shen showed concentration-dependent protein binding in serum. The free apparent digoxin concentration was 0.30 ng/mL (0.38 nmol/L) in Dan Shen pool 2, in which the total apparent digoxin concentration was 0.93 ng/mL (1.19 nmol/L). However, in Dan Shen pool 3, the apparent free digoxin concentration was 0.98 ng/mL (1.26 nmol/L); the apparent total digoxin concentration was 1.28 ng/mL (1.64 nmol/L). Therefore, the free fraction varied from 32.3% to 76.6%. In contrast, Lu-Shen-Wan showed fairly constant protein binding over the concentration range. The free fraction varied from 44.8% to 47.2%. For example, in Lu-Shen-Wan pool 2, the apparent total and free digoxin concentrations were 4.78 ng/mL (6.12 nmol/L) and 2.14 ng/mL (2.74 nmol/L), respectively. The apparent total and free digoxin concentrations in Lu-Shen-Wan pool 3 were 8.48 ng/mL (10.86 nmol/L) and 4.00 ng/mL (5.12 nmol/L), respectively.
We observed complete neutralization of the digoxin-like immunoreactive components of Dan Shen by Digibind as evidenced by complete disappearance of free apparent digoxin level in the protein-free ultrafiltrates when various amounts of Digibind were added to aliquots of the Dan Shen serum pools. For example, in Dan Shen pool 1, the free apparent digoxin concentration was 0.56 ng/mL (0.72 nmol/L). In the presence of 5 µg/mL of Digibind, the apparent free concentration was reduced to 0.23 ng/mL (0.29 nmol/L), and in the presence of 10 µg/mL of Digibind, the apparent free digoxin concentration was below the detection limit of the assay, indicating that Digibind is capable of binding digoxin-like immunoreactive components of Dan Shen. We observed similar removal of apparent free digoxin activity in the presence of Digibind in Dan Shen pools 2 and 3 ❚Table 1❚.
Digibind also is effective for neutralizing the free digoxin-like immunoreactive fraction of Lu-Shen-Wan. For example, in Lu-Shen-Wan pool 3, the free apparent digoxin concentration was 4.00 ng/mL (5.12 nmol/L). In the presence of 5 µg/mL of Digibind, the observed apparent free digoxin concentration was 0.22 ng/mL (0.28 nmol/L), which was just higher than the detection limit of the assay. In the presence of 10 µg/mL of Digibind, no apparent free digoxin concentration was observed in the protein-free ultrafiltrate, indicating that all free digoxin-like immunoreactive components of Lu-Shen-Wan were bound to Digibind ❚Table 2❚.
To validate that protein-free ultrafiltrate is a valid matrix for measuring apparent digoxin concentrations due to the presence of Dan Shen or Lu-Shen-Wan, we prepared ultrafiltrate from a drug-free serum pool. Then both the original serum pool and the corresponding protein-free ultrafiltrate were supplemented with the same amount of Dan Shen or Lu-Shen-Wan. Apparent digoxin concentrations were measured in the supplemented original serum and the corresponding protein-free ultrafiltrate. We observed comparable value between the serum and the corresponding protein-free ultrafiltrate, indicating that protein-free ultrafiltrate is a valid matrix for measuring apparent digoxin concentrations due to The total digoxin measurement is affected by Digibind. Interestingly, the apparent digoxin concentration due to LuShen-Wan also is affected by Digibind. We observed a significant decline in the total digoxin concentrations in the presence of Digibind. Similar declines also were observed in the serum pool aliquots supplemented with Lu-Shen-Wan and various amounts of Digibind ❚Figure 1❚.
Discussion
Our results clearly indicate that Digibind is capable of binding the free digoxin-like immunoreactive components of the Chinese medicines Lu-Shen-Wan and Dan Shen. Our initial in vitro observations raise the possibility of potential treatment of patients overdosed with Dan Shen or Lu-Shen-Wan. However, in vivo data with real patients are needed before this treatment can be used as standard practice in a hospital. To our knowledge, our preliminary results are the first report of the possibility of using Digibind for neutralizing the active components of the Chinese medicines Dan Shen and Lu-Shen-Wan. Moreover, by taking advantage of digoxin-like immunoreactivity of these active components, it also is possible to monitor this effect in a toxicology laboratory.
It has been established in the literature that the toxicologic actions of Chan Su and Lu-Shen-Wan are related to bufalin and similar steroids. 17, 18 Similarly, for Dan Shen, tanshinones are the active components. 19, 20 Because both classes of compound have substantial digoxin-like immunoreactivity, removal of the apparent digoxin concentration clearly indicates the successful binding of these active components with Digibind. Bufalin and the tanshinones can be analyzed by using sophisticated equipment, such as with high-performance liquid chromatography and mass spectrometry. [21] [22] [23] However, the cumbersome and timeconsuming analysis is beyond the reach of many small hospital laboratories. In contrast, the digoxin immunoassay is fast and used widely in hospital laboratories and can be used to detect Chan Su and Dan Shen overdoses if the patient is not exposed to digoxin. Our results also clearly indicate that free apparent digoxin concentrations should be measured to monitor the neutralization of free Dan Shen or Lu-Shen-Wan by Digibind. This also is a standard practice for monitoring the conditions of patients overdosed with digoxin and being treated with Digibind. Significant decreases in the free digoxin concentrations clearly indicate that Digibind actually binds the pharmacologically active free component. Moreover, the free digoxin concentration is not affected by Digibind because the molecular weight cutoff of the Centrifree filter is 30,000 d, while the molecular weight of Digibind is approximately 46,000 d. Therefore, Digibind is absent in the protein-free ultrafiltrates. In contrast, total digoxin measurements by digoxin immunoassays are affected by the presence of Digibind in the serum. 24, 25 Our results indicate that the measurement of apparent total digoxin concentrations due to the presence of the Chinese medicines Dan Shen and Lu-Shen-Wan also are affected significantly by Digibind.
Several digoxin immunoassays are commercially available. We demonstrated that the FPIA for digoxin has the highest cross-reactivity with the digoxin-like immunoreactive components of Dan Shen and Lu-Shen-Wan. For example, the chemiluminescent assay for digoxin does not cross-react with Lu-Shen-Wan. Although the Tina-Quant (Roche, Indianapolis, IN) and the Synchron LX digoxin assay (Beckman, Brea, CA) cross-react with Lu-Shen-Wan, none of these assays cross-reacts with Dan Shen. Moreover, the magnitude of cross-reactivity was much higher with the FPIA than with the other digoxin assays examined. 26, 27 Therefore, the FPIA for digoxin is most suitable for detection of these Chinese medicines in the serum or protein-free ultrafiltrate.
Digibind is capable of binding the free digoxin-like immunoreactive components of the Chinese medicines Dan Shen and Lu-Shen-Wan. This process can be monitored by measuring the apparent free digoxin concentration in the protein-free ultrafiltrate by using the FPIA for digoxin. 
